NEW YORK (GenomeWeb News) – OvaGene Oncology today announced it has completed licensing agreements with Norwegian researchers to validate new genomic technologies with the intention of developing them into clinical laboratory tests.
The Irvine, Calif.-based based firm has licensed a proprietary method from the University of Bergen Tech Office BTO for identifying high-risk endometrial cancer patients diagnosed with early-stage cancer. The technology can identify a molecular component in early-stage patients linked with high risk, OvaGene said in a statement.
It has also licensed a proprietary method from Medinnova for determining chemoradiation resistance in cervical cancer. Further studies are planned to validate the technology, which may allow patients to be tested for chemoradiation resistance before therapy is started.
Details about the agreements were not disclosed.